Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 0

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 0
---
Filed Pursuant to Rule 424(b)(4)

Registration No. 333-284495 and 333-285005

Prospectus

<div align='center'>Petros Pharmaceuticals, Inc.

13,950,012 Units, Each Unit Consisting of One Share of Common Stock, One Series A Warrant to Purchase 0.25 Share of Common Stock and One Series B Warrant to Purchase One Share of Common Stock

26,049,988 Pre-Funded Units, Each Unit Consisting of One Pre-Funded Warrant to Purchase One Share of Common Stock, One Series A Warrant to Purchase 0.25 Share of Common Stock and One Series B Warrant to Purchase One Share of Common Stock

Up to 156,049,988 Shares of Common Stock Underlying the Pre-Funded Warrants, Series A Warrants and Series B Warrants</div>

We are offering 13,950,012 units (the “Units”), each Unit consisting of one share of our common stock, $0.0001 par value per share (“common stock”), and an accompanying Series A warrant (the “Series A Warrants”) to purchase 0.25 share of common stock and an accompanying Series B warrant to purchase one share of common stock (the “Series B Warrants”, and, with the Series A Warrants, the “Series Warrants”), at the public offering price of $0.24 per Unit.

The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The exercisability of the Series Warrants will be available only upon receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market, including, but not limited to, with respect to (i) the issuance of all of the shares of common stock issuable upon exercise the Series Warrants in accordance with their terms (including adjustment provisions set forth therein), and (ii) to consent to any adjustment to the exercise price or number of shares of common stock underlying the Series Warrants in the event of a Share Combination Event and Dilutive Issuance (collectively, the “Warrant Stockholder Approval”). We have agreed to use our reasonable best efforts to obtain such approval within 60 days from the closing of this offering, and agreed to cause an additional stockholder meeting to be held every ninety days thereafter until (i) such Warrant Stockholder Approval is obtained. We cannot assure you that we will be able to obtain requisite Stockholder Approval